K92 Mining: Canaccord Reiterates $12 Price Target Following Bought Deal

K92 Mining Inc. (TSX: KNT) announced a $50 million bought deal this past week, selling 5,405,000 common shares at a price of $9.25 per share. The deal has an over-allotment option for underwriters to purchase an additional 810,825 shares for an additional $7.5 million. K92 said that they intend to use the proceeds for the “continued expansion of the Kainantu Gold Mine, exploration near-mine and regionally,” as well as for general working capital purposes.

K93 currently has 9 analysts covering the stock with an average 12-month price target of C$12.28, or an upside of roughly 40%. Out of the 9 analysts covering the stock, 4 of them have strong buy ratings while the other 5 have buy ratings. The street high sits at C$14 from 2 analysts and represents an upside of 60%.

In Canaccord’s note on the news release, they reiterate their speculative buy rating and C$12 12-month price target, saying that the bought deal helps de-risk the company’s planned expansion. The company is expected to commission its Stage 2A mill which would bring its throughput from 400ktpa to 500ktpa. This expansion is expected to cost roughly US$2.5 million and is expected to start commissioning later this year.

Canaccord is currently modeling that K92 will need initial capital of US$225 million and total capital of US$363 million from 2023 to 2024 to support their build-outs. This is above the company’s own estimates within its PEA of US$125 million of growth capital and US$240 million of total capital.

The company is also contemplating a US$100 million corporate facility, “that should provide additional flexibility and allow the company to continue its aggressive exploration program during the “Stage 3″ build.”

Canaccord now believes that the company has a “sizeable cash cushion” for all its upcoming expansions. More specifically, they believe that this will also allow the company to continue its exploration program even if gold drops to $1,500 an ounce. Though they do note that this cash comes with dilution, saying that this sort of funding “highlights the potential issue created by the current inflationary environment.”

Below you can see Canaccord’s updated estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Copper Is Heading To $30 And Silver To $200 | Craig Parry

Mako Mining Q3 Earnings: The Transitional Quarter

B2Gold Q3 Earnings: Goose Troubles Cloud The Narrative

Recommended

Selkirk Copper Appoints Two Members Of Selkirk First Nation To Leadership Team

Altamira Gold Appoints Dr Richard Sillitoe, Porphyry Expert, As Technical Advisor

Related News

BMO Reiterates US$34.50 Price Target On Barrick Gold Following Investor Day

This past week, BMO Capital Markets came out with a note on Barrick Gold’s (TSX:...

Saturday, November 28, 2020, 01:43:00 PM

Canaccord Reiterates $0.00 Price Target On Medmen

Medmen Enterprises’ (CSE: MMEN) reported their fiscal third quarter 2021 financial results on May 11th...

Friday, May 14, 2021, 04:38:00 PM

Canopy Growth: Analysts Expect Q2 Revenues Of $142.5 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Thursday, November 4, 2021, 03:16:00 PM

Cresco Labs: Canaccord Lowers Target On Adjusted EBITDA Miss

On August 13, Cresco Labs (CSE: CL) announced its second quarter financials. The company had...

Thursday, August 19, 2021, 11:36:00 AM

Well Health: Consensus Price Target Climbs To $11.83 Following MyHealth Acquisition

WELL Health Technologies Corp. (TSX: WELL) this week announced that they would be acquiring MyHealth...

Thursday, June 10, 2021, 11:46:00 AM